All In Biotech

NDA 212614 · Boehringer Ingelheim

Trijardy Xr

Empagliflozin, Linagliptin, Metformin Hydrochloride · Oral · Sodium-Glucose Cotransporter 2 Inhibitor; Dipeptidyl Peptidase 4 Inhibitor

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jan 27, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

544

123 Phase 3, 99 recruiting

FAERS reports

124

45 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...

What it is approved for

From the label in effect Aug 24, 2026.

TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease [see Clinical Studies (14.2) ] . TRIJARDY XR is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease. ( 1 ) Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Has not been studied in patients with a history of pancreatitis. ( 1 ) Limitations of Use TRIJARDY XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients [see Warnings and Precautions (5.2) ] . TRIJARDY XR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRIJARDY XR [see Warnings and Precautions (5.3) ].

Mechanism: TRIJARDY XR TRIJARDY XR contains: empagliflozin, a SGLT2 inhibitor, linagliptin, a DPP-4 inhibitor, and metformin HCl, a biguanide. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Linagliptin Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • TRIJARDY XR · EMPAGLIFLOZIN 25MG; LINAGLIPTIN 5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • TRIJARDY XR · EMPAGLIFLOZIN 10MG; LINAGLIPTIN 5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • TRIJARDY XR · EMPAGLIFLOZIN 12.5MG; LINAGLIPTIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • TRIJARDY XR · EMPAGLIFLOZIN 5MG; LINAGLIPTIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Empagliflozin" as an intervention, any sponsor and status, largest first.

All 544 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased20
  • off label use11
  • fatigue10
  • diarrhoea7
  • headache6
  • nausea6
  • vomiting6
  • weight decreased6
  • dizziness5
  • drug ineffective5
  • glycosylated haemoglobin increased5
  • decreased appetite4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20204
202145
202223
202317
202414
202510
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trijardy XR (Empaglifloz/Linaglip/Metformin)

2024 spending

$99.1M

Beneficiaries

21,512

112,533 claims

Per beneficiary

$4,609

$14.15 per unit

View as table
YearSpending
2020$1,450,472
2021$17,542,710
2022$43,294,714
2023$76,136,040
2024$99,142,501

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 813 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.